Xeris Biopharma (XERS) Competitors $4.13 +0.03 (+0.73%) Closing price 04/23/2025 04:00 PM EasternExtended Trading$4.14 +0.01 (+0.24%) As of 07:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XERS vs. XENE, ACAD, IBRX, APLS, TWST, MLTX, AMRX, RXRX, VCEL, and MIRMShould you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Xenon Pharmaceuticals (XENE), ACADIA Pharmaceuticals (ACAD), ImmunityBio (IBRX), Apellis Pharmaceuticals (APLS), Twist Bioscience (TWST), MoonLake Immunotherapeutics (MLTX), Amneal Pharmaceuticals (AMRX), Recursion Pharmaceuticals (RXRX), Vericel (VCEL), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. Xeris Biopharma vs. Xenon Pharmaceuticals ACADIA Pharmaceuticals ImmunityBio Apellis Pharmaceuticals Twist Bioscience MoonLake Immunotherapeutics Amneal Pharmaceuticals Recursion Pharmaceuticals Vericel Mirum Pharmaceuticals Xenon Pharmaceuticals (NASDAQ:XENE) and Xeris Biopharma (NASDAQ:XERS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, community ranking, profitability and media sentiment. Does the MarketBeat Community favor XENE or XERS? Xenon Pharmaceuticals received 277 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 70.00% of users gave Xeris Biopharma an outperform vote while only 69.74% of users gave Xenon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformXenon PharmaceuticalsOutperform Votes42469.74% Underperform Votes18430.26% Xeris BiopharmaOutperform Votes14770.00% Underperform Votes6330.00% Which has more risk and volatility, XENE or XERS? Xenon Pharmaceuticals has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Is XENE or XERS more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%. Xeris Biopharma's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Xenon PharmaceuticalsN/A -24.69% -23.68% Xeris Biopharma -33.69%N/A -17.38% Which has preferable earnings and valuation, XENE or XERS? Xeris Biopharma has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenon Pharmaceuticals$9.43M305.12-$182.39M-$3.02-12.45Xeris Biopharma$203.07M3.13-$62.26M-$0.38-10.87 Do institutionals & insiders have more ownership in XENE or XERS? 95.4% of Xenon Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 5.5% of Xenon Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer XENE or XERS? In the previous week, Xenon Pharmaceuticals had 7 more articles in the media than Xeris Biopharma. MarketBeat recorded 14 mentions for Xenon Pharmaceuticals and 7 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.23 beat Xenon Pharmaceuticals' score of 0.96 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer XENE or XERS? Xenon Pharmaceuticals currently has a consensus target price of $56.78, indicating a potential upside of 51.04%. Xeris Biopharma has a consensus target price of $6.10, indicating a potential upside of 47.70%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Xenon Pharmaceuticals is more favorable than Xeris Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryXenon Pharmaceuticals and Xeris Biopharma tied by winning 9 of the 18 factors compared between the two stocks. Get Xeris Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XERS vs. The Competition Export to ExcelMetricXeris BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$631.15M$6.51B$5.35B$7.51BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-9.187.0021.9618.05Price / Sales3.13260.09396.51104.31Price / CashN/A65.6738.2034.62Price / Book-82.606.346.734.14Net Income-$62.26M$142.49M$3.21B$247.59M7 Day Performance0.49%6.44%3.97%3.51%1 Month Performance-29.64%-9.07%-7.03%-5.80%1 Year Performance134.66%-2.74%15.46%2.83% Xeris Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XERSXeris Biopharma4.1788 of 5 stars$4.13+0.7%$6.10+47.7%+132.0%$631.15M$203.07M-9.18290Positive NewsGap UpXENEXenon Pharmaceuticals2.7198 of 5 stars$33.44+6.5%$57.38+71.6%-8.5%$2.56B$9.43M-11.86210Analyst UpgradeACADACADIA Pharmaceuticals4.1208 of 5 stars$14.86+1.9%$23.93+61.1%-12.5%$2.48B$957.80M19.05510Positive NewsGap UpIBRXImmunityBio1.8896 of 5 stars$2.89+9.9%$12.19+321.7%-51.0%$2.47B$14.75M-3.14590Analyst ForecastGap UpAPLSApellis Pharmaceuticals4.0804 of 5 stars$19.33-0.5%$45.59+135.8%-64.1%$2.43B$781.37M-9.52770Analyst ForecastPositive NewsTWSTTwist Bioscience3.6264 of 5 stars$39.82+2.5%$52.80+32.6%+19.4%$2.38B$330.19M-11.78990Positive NewsGap UpMLTXMoonLake Immunotherapeutics2.1723 of 5 stars$35.75+2.4%$80.50+125.2%-8.6%$2.29BN/A-27.712News CoveragePositive NewsGap UpAMRXAmneal Pharmaceuticals3.0418 of 5 stars$7.21+3.3%$10.80+49.8%+35.3%$2.23B$2.79B-10.607,600Positive NewsGap UpRXRXRecursion Pharmaceuticals2.3699 of 5 stars$5.51-4.3%$8.20+48.8%-27.5%$2.21B$58.49M-3.60400Gap UpHigh Trading VolumeVCELVericel2.6871 of 5 stars$41.230.0%$60.86+47.6%-13.7%$2.07B$237.22M687.28300Positive NewsGap UpMIRMMirum Pharmaceuticals3.9306 of 5 stars$39.59+0.0%$58.20+47.0%+62.2%$1.94B$336.89M-19.60140News CoveragePositive News Related Companies and Tools Related Companies XENE Alternatives ACAD Alternatives IBRX Alternatives APLS Alternatives TWST Alternatives MLTX Alternatives AMRX Alternatives RXRX Alternatives VCEL Alternatives MIRM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XERS) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XERS Stock Free XERS Stock Alerts